Advanced in Juvenile Temporal Arteritis

Dr. Dhiman Basu

Rheumatology
American Arthritis And Rheumatology Associates-Tx PLLC
5009 Heritage Ave, 
Colleyville, TX 
Accepting New Patients
Offers Telehealth
Advanced in Juvenile Temporal Arteritis
American Arthritis And Rheumatology Associates-Tx PLLC
5009 Heritage Ave, 
Colleyville, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dhiman Basu is a Rheumatologist in Colleyville, Texas. Dr. Basu is rated as an Advanced provider by MediFind in the treatment of Juvenile Temporal Arteritis. His top areas of expertise are Rheumatoid Arthritis (RA), Fibromyalgia, Undifferentiated Connective Tissue Disease (UCTD), and Sjogren Syndrome. Dr. Basu is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in MI
Hospital Affiliations
Texas Health Harris Methodist Hurst-Euless-Bedford
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cook Children's Health Plan
  • MANAGED MEDICAID PLAN
EMI Health
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

AMERICAN ARTHRITIS AND RHEUMATOLOGY ASSOCIATES-TX PLLC
5009 Heritage Ave, Colleyville, TX 76034

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in SLE and in CLE (SCLE and/or DLE) Participants Receiving Standard of Care (WILLOW)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in SLE and in CLE (SCLE and/or DLE) Participants Receiving Standard of Care (WILLOW)
Enrollment Status: Completed
Publish Date: December 05, 2024
Intervention Type: Drug
Study Drug: M5049
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Other
Study Drug: VIB7734
Study Phase: Phase 2
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 11 Less Clinical Trials

2 Total Publications

Acthar® Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence.
Acthar® Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence.
Journal: Clinical drug investigation
Published: August 23, 2023
Similar Doctors
Advanced in Juvenile Temporal Arteritis
Dr. Kathryn H. Dao
Rheumatology
Advanced in Juvenile Temporal Arteritis
Dr. Kathryn H. Dao
Rheumatology
9900 N Central Expy Ste 550, 
Dallas, TX 
 (20.8 miles away)
214-648-5295
Languages Spoken:
English
See accepted insurances

Kathryn Dao is a Rheumatologist in Dallas, Texas. Dr. Dao is rated as a Distinguished provider by MediFind in the treatment of Juvenile Temporal Arteritis. Her top areas of expertise are Sjogren Syndrome, Necrotizing Vasculitis, Psoriatic Arthritis, and Rheumatoid Arthritis (RA).

Advanced in Juvenile Temporal Arteritis
Dr. Matthew S. Hogenmiller
Rheumatology | Internal Medicine
Advanced in Juvenile Temporal Arteritis
Dr. Matthew S. Hogenmiller
Rheumatology | Internal Medicine

Rheumatology Associates

4370 Medical Arts Dr Ste, 
Flower Mound, TX 
 (38.1 miles away)
972-724-1707
Experience:
31+ years
Languages Spoken:
English
See accepted insurances

Matthew Hogenmiller is an Internal Medicine specialist and a Rheumatologist in Flower Mound, Texas. Dr. Hogenmiller has been practicing medicine for over 31 years and is rated as a Distinguished provider by MediFind in the treatment of Juvenile Temporal Arteritis. His top areas of expertise are Rheumatoid Arthritis (RA), Fibromyalgia, Necrotizing Vasculitis, and Raynaud Phenomenon.

Advanced in Juvenile Temporal Arteritis
Dr. Nuha R. Said
Rheumatology
Advanced in Juvenile Temporal Arteritis
Dr. Nuha R. Said
Rheumatology

University Of Texas Southwestern Medical Center At Dallas

600 S Main St, 
Fort Worth, TX 
 (16.3 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nuha Said is a Rheumatologist in Fort Worth, Texas. Dr. Said is rated as an Advanced provider by MediFind in the treatment of Juvenile Temporal Arteritis. Her top areas of expertise are Juvenile Temporal Arteritis, Giant Cell Arteritis (GCA), Temporal Arteritis, and Systemic Lupus Erythematosus (SLE).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Basu's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile